MS Views and News (MSVN)

FDA Approves First Biosimilar to Treat Multiple Sclerosis - Details Created on Thursday, 24 August 2023 19:52 ,  /PRNewswire/ -- The U.S. Food and Drug Administration today approved Tyruko (natalizumab-sztn), the first biosimilar to Tysabri (natalizumab) injection for the treatment of adults with relapsing forms of multiple sclerosis (MS).

* MSVN Online webinars and "In-Person" educational program listings: * ALL events in bold lettering are In-person/Virtual (Hybrid) 2023 ------------------------------ July 07.15.23 - Compass to MS Care - Memphis, TN - (Hybrid) 07.17.23 - Chair Pilates 07.18.23 - MS Conversations NOW - Patient's Voices 07.26.23 - MS Wellness Chat ------------------------------- August 08.08.23 - MS Patients Voices 08.09.23 - MS Views NOW - 08.10.23 - MS NeuroTV 08.14.23 - Phys Therapy 08.21.23 - Chair Pilates...

EBV-Autoimmune disease treatment that could expand overall MS treatment program options Details Created on Sunday, 26 March 2023 14:33 by Alan M Dattner, MD     [email protected] I was excited to see the studies that showed a 32-fold increase in MS in recruits who became Epstein-Barr virus (EBV) positive[i]. Howard Weiner, MD at Harvard has described targeting EBV to treat MS.[ii] Over 200 articles on PubMed discuss the link between EBV and MS.

Cycle Pharmaceuticals to launch TASCENSO ODT® (fingolimod) in US in Q1 2023 Details Created on Saturday, 25 March 2023 11:11 Eligible patients will receive full MS patient support program through Cycle Vita™ Boston, Massachusetts and San Jose, California – November 1, 2022 – Cycle Pharmaceuticals Ltd (Cycle) is pleased to announce its intention to commercialize TASCENSO ODT® (fingolimod) in the US multiple sclerosis (MS) market in Q1 2023.

The images used on this site do not necessarily represent actual multiple sclerosis patients. The information found on this site or linked outside the site is not a substitute for your doctor's medical advice. You should promptly consult a medical professional if you have concerns about your health. COMPLETE WEBSITE TERMS AND CONDITIONS MS Views and News Digital Policy and Disclaimer All information shared on this website is for educating members of the MS community.

Do you have multiple sclerosis (MS) and are you pregnant? Then you may be able to take part in a global registry of women with MS who are pregnant and either have or have not received OCREVUS® (ocrelizumab) during or within 6 months before their pregnancy. About pregnancy and multiple sclerosis The effects of a particular medicine on the health of an unborn baby are often unknown because pregnant women are not usually included in clinical research studies to test a potential new medicine.

MS Views and News Providing Education & Information to the Multiple Sclerosis Community. Error JLIB_APPLICATION_ERROR_COMPONENT_NOT_LOADING JLIB_APPLICATION_ERROR_COMPONENT_NOT_LOADING Error loading component: com_content, 1 Error loading component: com_content, 1 Error loading component: com_content, 1 Error loading component: com_content, 1

MS Views and News Providing Education & Information to the Multiple Sclerosis Community. Error JLIB_APPLICATION_ERROR_COMPONENT_NOT_LOADING JLIB_APPLICATION_ERROR_COMPONENT_NOT_LOADING Error loading component: com_content, 1 Error loading component: com_content, 1 Error loading component: com_content, 1 Error loading component: com_content, 1

Upcoming MSVN Virtual MS Educational Programs To receive information of our upcoming events, simply Register with us by clicking on the "SIGN Up for NEWS" button on top right of this page. Stay up-to-date by checking this page often.

FDA approves Novartis Kesimpta® (ofatumumab), the first and only self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis Details Created on Thursday, 20 August 2020 16:04 ** Kesimpta delivers powerful efficacy with a favorable safety profile and can be self-administered at home, addressing significant unmet needs for people living with relapsing forms of multiple sclerosis (RMS)1 ** Approval based on two Phase III ASCLEPIOS studies demonstrating significant...